Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Akers Biosciences, Inc.    AKER

AKERS BIOSCIENCES, INC.

(AKER)
  Report
 SummaryQuotesChartsNewsCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/14/2021 01/15/2021 01/19/2021 01/20/2021 01/21/2021 Date
2.69(c) 2.65(c) 2.52(c) 2.77(c) 2.72 Last
368 258 513 258 401 704 1 178 350 201 362 Volume
+1.51% -1.49% -4.91% +9.92% -1.81% Change
More quotes
Financials (USD)
Sales 2018 1,67 M - -
Net income 2018 -10,8 M - -
Net cash position 2018 5,46 M - -
P/E ratio 2018 -1,22x
Yield 2018 -
Sales 2019 1,58 M - -
Net income 2019 -3,89 M - -
Net cash position 2019 9,68 M - -
P/E ratio 2019 -0,50x
Yield 2019 -
Capitalization 24,5 M 24,5 M -
EV / Sales 2018 5,19x
EV / Sales 2019 -3,83x
Nbr of Employees 12
Free-Float 84,1%
More Financials
Company
Akers Biosciences, Inc. develops, manufactures, and supplies point-of-care screening and testing products designed to bring health-related information directly to the patient or clinician. The Company’s product offerings focus on delivering diagnostic assistance in a variety of healthcare fields/specialties, including diagnostic rapid manual point-of-care tests for the detection of allergic reactions to Heparin... 
More about the company
All news about AKERS BIOSCIENCES, INC.
2020AKERS BIOSCIENCES INVESTOR ALERT BY : Kahn Swick & Foti, LLC Investigates Merge..
BU
2020AKERS BIOSCIENCES : ' Proposed Merger Partner MyMD Pharmaceuticals Announces Iss..
BU
2020AKERS BIOSCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
2020AKERS BIOSCIENCES, INC. : Other Events, Financial Statements and Exhibits (form ..
AQ
2020AKERS BIOSCIENCES, INC. : Other Events, Financial Statements and Exhibits (form ..
AQ
2020REMINDER : Akers Biosciences Schedules Conference Call to Discuss Merger with My..
BU
2020AKERS BIOSCIENCES INVESTOR ALERT BY : Kahn Swick & Foti, LLC Investigates Merge..
BU
2020AKERS BIOSCIENCES : Management's Discussion and Analysis of Financial Condition ..
AQ
2020AKERS BIOSCIENCES, INC. : Other Events (form 8-K)
AQ
2020AKERS BIOSCIENCES : Entry into a Material Definitive Agreement, Unregistered Sal..
AQ
2020AKERS BIOSCIENCES, INC. : Entry into a Material Definitive Agreement, Unregister..
AQ
2020AKERS MERGER INVESTIGATION : Halper Sadeh LLP Announces Investigation Into Wheth..
BU
2020Akers Biosciences, MyMD Pharmaceuticals Ink Merger Agreement
MT
2020AKERS BIOSCIENCES : and MyMD Pharmaceuticals Sign Definitive Merger Agreement
BU
2020AKERS BIOSCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
More news
News in other languages on AKERS BIOSCIENCES, INC.

- No features available -

More news
Chart AKERS BIOSCIENCES, INC.
Duration : Period :
Akers Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AKERS BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Managers and Directors
NameTitle
Christopher C. Schreiber President & Chief Executive Officer
Joshua Nathaniel Silverman Chairman
Stuart Benson Chief Financial Officer
Bill Joe White Independent Non-Executive Director
Robert C. Schroeder Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
AKERS BIOSCIENCES, INC.39.20%25
ABBOTT LABORATORIES3.11%192 878
MEDTRONIC PLC1.84%159 248
BECTON, DICKINSON AND COMPANY5.23%75 845
HOYA CORPORATION-5.12%49 012
ALIGN TECHNOLOGY, INC.5.61%43 952